Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of Intravenous Erythromycin on Gastric Emptying in Non-fasted Patients Before Emergency Total Anesthesia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Christoph Czarnetzki, University Hospital, Geneva
ClinicalTrials.gov Identifier:
NCT00827216
First received: January 21, 2009
Last updated: April 12, 2013
Last verified: April 2013
  Purpose

In this study the investigators want to investigate the effect of a short intravenous infusion of Erythromycine on gastric emptying on patients considered "full stomac" and scheduled for Emergency operation. A gastroscopy will be done after intubation to controll the effect of the perfusion.


Condition Intervention Phase
Aspiration of Gastric Contents
Gastric Emptying
Drug: Placebo
Drug: Erythromycin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Intravenous Erythromycin on Gastric Emptying in Patients Undergoing Rapid Sequence Intubation for Full Stomach - A Randomised, Placebo-controlled, Double-blind Study

Resource links provided by NLM:


Further study details as provided by University Hospital, Geneva:

Primary Outcome Measures:
  • Immediately after intubation an upper GI endoscopy will be done. The following primary endpoint will be recorded: Stomach clear from any content: yes or no (dichotomous). [ Time Frame: 10 minutes ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Acidity and Estimation of the volume of gastric content if stomach not empty (ml). [ Time Frame: 10 minutes ] [ Designated as safety issue: No ]
  • Drug-related allergic reactions. [ Time Frame: 30 minutes ] [ Designated as safety issue: Yes ]
  • Arrhythmia. [ Time Frame: 30 minutes ] [ Designated as safety issue: Yes ]
  • Gastrointestinal cramps after study drug administration but before intubation. [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]
  • Nausea or vomiting after study drug administration but before intubation. [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]
  • Regurgitation with or without broncho-aspiration at induction. [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]

Enrollment: 132
Study Start Date: January 2009
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Physiologic saline Drug: Placebo
For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
Active Comparator: Erythromycine Drug: Erythromycin
For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
Other Name: Erythrocine®

Detailed Description:

Urgent or emergency surgery requires that fasting rules observed in elective settings are not respected. Patients who are anesthetized in such conditions are at risk for regurgitation and subsequent broncho-aspiration during induction of anaesthesia due to a full stomach; they often have ingested food or liquids before the injury, or they may have swallowed blood from oral or nasal injuries. Also, gastric emptying is delayed in these patients due to the stress of trauma.1 Already in 1946, Mendelson described the consequences of bronchoaspiration.2 Since, anaesthetists and emergency physicians have tried to avoid broncho-aspiration in emergency patients using premedication with pro-kinetic drugs (for instance, metoclopramide) or its complications with antacid substances, and through the use of a rapid sequence intubation procedure with cricoid pressure.

The incidence of aspiration is low, about 1.4 to 6 in 10'000 anaesthetics.3 About 6 in 100'000 anaesthetics will lead to a pulmonary complication due to broncho-aspiration and about 1 in 100'000 patients is likely to die due to aspiration.4 Thus, although episodes of broncho-aspiration are rare, efficacious prevention of this potentially lethal complication is important. One method to reduce the risk of broncho-aspiration during induction of anaesthesia is the pharmacological reduction of the gastric content (i.e. pre-treatment).

The primary objective of this study is to investigate the effect of a short intravenous infusion of erythromycin 3 mg/kg, administered 20 min before intubation on gastric emptying, in adults scheduled for rapid sequence intubation for full stomach. After intubation a gastroscopy will be done to see if there is any content in the stomac. The secondary objective is the assessment of tolerability and safety of a single intravenous dose of preoperative erythromycin in surgical patients.

This study is a single centre, stratified (according to emergency setting), randomised, placebo-controlled, double-blinded study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults, age ≥18 years, male or female.
  • American Society of Anaesthesiology [ASA] status I, II or III.
  • Non-starving patients presenting for surgery.
  • Patients able to read and understand the information sheet and to sign the consent form.
  • If the patient is female and of childbearing potential, she must have a negative pregnancy test

Exclusion Criteria:

  • A history of allergy or hypersensitivity to erythromycin or other macrolides.
  • Concomitant use of terfenadine, astemizole, cisapride, pimozid, cyclosporine, clarithromycine.
  • Patient with acute intermittent porphyria.
  • Acute or subacute necrosis of the liver, acute or subacute hepatitis, acute liver trauma
  • Acute renal failure, acute glomerulonephritis, nephritic syndrome, chronic renal failure with electrolyte disorders, uremia
  • Exacerbated asthma, exacerbated chronic obstructive lung disease, acute pulmonary infection
  • Coronary heart disease (unstable angina, MI within the last 6 months), decompensated cardiac insufficiency, aortic aneurysm
  • Polyneuropathy (for instance, due to diabetes mellitus)
  • Patients with oesophageal and pharyngeal disease (i.e. oesophageal varices, oesophageal and pharyngeal cancer, Zenker's diverticulum).
  • Status after gastric surgery, gastric bypass surgery, Nissen operation
  • Patients with life threatening illness or injury needing immediate surgery
  • Patients with moderate to severe head trauma (GCS on admission <13)
  • Psychological or psychiatric disorders.
  • Dementia or inability to understand the study protocol.
  • Women who are pregnant or are breast feeding.
  • Patient scheduled for ileus surgery.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00827216

Locations
Switzerland
University Hospital of Geneva
Geneva, Switzerland, 1211
Sponsors and Collaborators
University Hospital, Geneva
Investigators
Principal Investigator: Christoph A Czarnetzki, MD, MBA Division of Anesthesiology, University Hospital of Geneva
Study Chair: Martin R Tramer, MD, PhD Division of Anesthesiology, University Hospital of Geneva
  More Information

Publications:
Responsible Party: Christoph Czarnetzki, Responsable Investigator, University Hospital, Geneva
ClinicalTrials.gov Identifier: NCT00827216     History of Changes
Other Study ID Numbers: NAC 06-225, Swissmedic 2008 DR 2321
Study First Received: January 21, 2009
Last Updated: April 12, 2013
Health Authority: Switzerland: Swissmedic

Keywords provided by University Hospital, Geneva:
Gastric emptying
emergency anesthesia
gastric emptying
intravenous erythromycin

Additional relevant MeSH terms:
Anesthetics
Erythromycin
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Anti-Bacterial Agents
Anti-Infective Agents
Central Nervous System Agents
Central Nervous System Depressants
Enzyme Inhibitors
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Synthesis Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 23, 2014